+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 120 Pages
  • August 2024
  • Region: Global
  • Grand View Research
  • ID: 5998930
Description Jump to:

Metastatic Lung Adenocarcinoma Treatment Market Growth & Trends

The global metastatic lung adenocarcinoma treatment market size is anticipated to reach USD 9.3 billion by 2030, growing at a CAGR of 11.3% from 2024 to 2030. This expansion is fueled by several key factors, including the rising prevalence of the disease, advancements in treatment technologies, and supportive regulatory and government initiatives. According to the World Health Organization (WHO), lung cancer remains the most diagnosed cancer globally, with approximately 2.5 million new cases each year, representing 12.4% of all new cancer cases. This high incidence rate underscores the urgent demand for effective treatment solutions.

Recent developments in treatment have significantly contributed to market growth. Innovations such as targeted therapies, including ALK inhibitors and EGFR inhibitors, have revolutionized the management of metastatic lung adenocarcinoma. For instance, in March 2024, Pfizer Inc. published long-term follow-up data from the Phase 3 CROWN trial. This study assessed the effectiveness of LORBRENA, a third-generation ALK inhibitor, in comparison to XALKORI for patients with newly diagnosed, ALK-positive advanced non-small cell lung cancer (NSCLC). Drugs such as LORBRENA (lorlatinib) and TAGRISSO (osimertinib) offer new hope for patients, leading to improved survival rates and quality of life. Moreover, the increasing adoption of immunotherapies, such as checkpoint inhibitors, has further expanded treatment options.

Regulatory bodies play a crucial role in facilitating market growth. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented expedited approval processes for promising therapies, accelerating patient access to new treatments. Additionally, government initiatives, such as the National Cancer Moonshot Initiative in the U.S. and the European Union's Horizon Europe program, are funding research and supporting the development of novel therapies, contributing to the market's expansion and the advancement of treatment options for metastatic lung adenocarcinoma.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights

  • Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, radiation therapy and others. In 2023, the chemotherapy segment accounted for the largest revenue share of 33.2% in metastatic lung adenocarcinoma treatment market
  • The hospital segment accounts for the largest revenue share of 64.3% in 2023. Hospitals are typically equipped with advanced diagnostic and treatment facilities, making them the preferred setting for complex cancer care
  • The North American metastatic lung adenocarcinoma treatment market is driven by high disease prevalence and a strong emphasis on innovation. The rising incidence of lung cancer, particularly adenocarcinoma, has led to the adoption of more personalized treatment strategies tailored to the genetic profiles of tumors

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment Outlook
2.2.2. End Use Outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Metastatic Lung Adenocarcinoma Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. The increasing incidence of lung cancer
3.2.1.2. Advancements in targeted therapies and immunotherapies
3.2.1.3. The growing emphasis on personalized medicine
3.2.1.4. The rising demand for early detection and screening programs
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatments
3.2.2.2. Limited availability of skilled healthcare professionals
3.3. Metastatic Lung Adenocarcinoma Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Metastatic Lung Adenocarcinoma Treatment Market: Treatments Estimates & Trend Analysis
4.1. Global Metastatic Lung Adenocarcinoma Treatment Market: Treatment Dashboard
4.2. Global Metastatic Lung Adenocarcinoma Treatment Market: Treatment Movement Analysis
4.3. Global Metastatic Lung Adenocarcinoma Treatment Market by Treatment, Revenue
4.4. Chemotherapy
4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Targeted Therapy
4.5.1. Targeted Therapy market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Immunotherapy
4.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Radiation Therapy
4.7.1. Radiation Therapy market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Other
4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Metastatic Lung Adenocarcinoma Treatment Market: End Use Estimates & Trend Analysis
5.1. Global Metastatic Lung Adenocarcinoma Treatment Market: End Use Dashboard
5.2. Global Metastatic Lung Adenocarcinoma Treatment Market: End Use Movement Analysis
5.3. Global Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
5.4. Hospitals
5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Specialty Clinics
5.5.1. Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Other
5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Metastatic Lung Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis by Treatments, and End Use
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Argentina
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Vendor Landscape
7.2.1. List of key distributors and channel partners
7.2.2. Key company market share analysis, 2023
7.2.3. Pfizer
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Eli Lilly and Company
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. AstraZeneca
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Bristol-Myers Squibb Company
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Boehringer Ingelheim International GmbH
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Novartis AG
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Merck KGaA (EMD Serono)
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. F. Hoffmann-La Roche
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. GSK Plc.
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. AbbVie Inc.
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
List of Tables
Table 1 List Of Abbreviation
Table 2 North America Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
Table 3 North America Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 4 North America Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 5 U.S. Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 6 U.S. Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 7 Canada Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 8 Canada Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 9 Mexico Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 10 Mexico Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 11 Europe Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
Table 12 Europe Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 13 Europe Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 14 Germany Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 15 Germany Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 16 UK Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 17 UK Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 18 France Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 19 France Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 20 Italy Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 21 Italy Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 22 Spain Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 23 Spain Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 24 Denmark Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 25 Denmark Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 26 Sweden Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 27 Sweden Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 28 Norway Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 29 Norway Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 30 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
Table 31 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 32 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 33 China Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 34 China Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 35 Japan Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 36 Japan Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 37 India Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 38 India Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 39 South Korea Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 40 South Korea Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 41 Australia Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 42 Australia Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 43 Thailand Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 44 Thailand Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 45 Latin America Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
Table 46 Latin America Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 47 Latin America Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 48 Brazil Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 49 Brazil Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 50 Argentina Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 51 Argentina Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 52 MEA Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
Table 53 MEA Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 54 MEA Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 55 South Africa Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 56 South Africa Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 59 UAE Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 60 UAE Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
Table 61 Kuwait Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
Table 62 Kuwait Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Metastatic Lung Adenocarcinoma Treatment Market: Market Outlook
Fig. 14 Metastatic Lung Adenocarcinoma Treatment Competitive Insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Metastatic Lung Adenocarcinoma Treatment Market Driver Impact
Fig. 18 Metastatic Lung Adenocarcinoma Treatment Market Restraint Impact
Fig. 19 Metastatic Lung Adenocarcinoma Treatment Market Strategic Initiatives Analysis
Fig. 20 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Movement Analysis
Fig. 21 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Outlook And Key Takeaways
Fig. 22 Chemotherapy market estimates and forecast, 2018 - 2030
Fig. 23 Targeted therapy market estimates and forecast, 2018 - 2030
Fig. 24 Immunotherapy market estimates and forecast, 2018 - 2030
Fig. 25 Radiation Therapy market estimates and forecast, 2018 - 2030
Fig. 26 Other market estimates and forecast, 2018 - 2030
Fig. 27 Metastatic Lung Adenocarcinoma Treatment Market: End Use Movement Analysis
Fig. 28 Metastatic Lung Adenocarcinoma Treatment Market: End Use Outlook And Key Takeaways
Fig. 29 Hospitals market estimates and forecast, 2018 - 2030
Fig. 30 Specialty clinics market estimates and forecast, 2018 - 2030
Fig. 31 Other market estimates and forecast, 2018 - 2030
Fig. 32 Global Metastatic lung adenocarcinoma treatment Market: Regional Movement Analysis
Fig. 33 Global Metastatic lung adenocarcinoma treatment Market: Regional Outlook And Key Takeaways
Fig. 34 Global Metastatic lung adenocarcinoma treatment market share and leading players
Fig. 35 North America, by country
Fig. 36 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 U.S. key country dynamics
Fig. 38 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Canada key country dynamics
Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Mexico key country dynamics
Fig. 42 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 UK key country dynamics
Fig. 45 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Germany key country dynamics
Fig. 47 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 France key country dynamics
Fig. 49 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Italy key country dynamics
Fig. 51 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Spain key country dynamics
Fig. 53 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Denmark key country dynamics
Fig. 55 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Sweden key country dynamics
Fig. 57 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Norway key country dynamics
Fig. 59 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 China key country dynamics
Fig. 62 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Japan key country dynamics
Fig. 64 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 India key country dynamics
Fig. 66 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Thailand key country dynamics
Fig. 68 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 South Korea key country dynamics
Fig. 70 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Australia key country dynamics
Fig. 72 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Brazil key country dynamics
Fig. 75 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Argentina key country dynamics
Fig. 77 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 South Africa key country dynamics
Fig. 80 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Saudi Arabia key country dynamics
Fig. 82 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 UAE key country dynamics
Fig. 84 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 Kuwait key country dynamics
Fig. 86 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Market share of key market players- Metastatic lung adenocarcinoma treatment market

Companies Mentioned

  • Pfizer
  • Eli Lilly and Company
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Merck KGaA (EMD Serono)
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • AbbVie Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedAugust 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 4.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.3 Billion
Compound Annual Growth Rate11.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Breast Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Breast Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Lung Adenocarcinoma - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Lung Adenocarcinoma - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032 - Product Image

Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • 630 Pages
  • Global
From
Non-Small Cell Lung Cancer (NSCLC) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Non-Small Cell Lung Cancer (NSCLC) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 110 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.